FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069496710> ?p ?o ?g. }

• W2069496710 endingPage "711" @default.
• W2069496710 startingPage "700" @default.
• W2069496710 abstract "In Brief Objective: This study assessed the efficacy, safety, and tolerability of the serotonin-norepinephrine reuptake inhibitor desvenlafaxine and the selective serotonin reuptake inhibitor escitalopram for major depressive disorder (MDD) in postmenopausal women. Methods: In this randomized, double-blind study, postmenopausal outpatients (aged 40-70 y) with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition MDD received flexible-dose desvenlafaxine (100-200 mg/d) or escitalopram (10-20 mg/d) for 8 weeks. Acute-phase responders, that is, women with a 50% or greater reduction from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D17) total score, were eligible to continue the same double-blind treatment in the 6-month continuation phase. The primary efficacy outcomes were mean change from baseline in HAM-D17 total score (acute phase), analyzed using a mixed-effects model for repeated measures, and the proportion of women who maintained response (continuation phase), analyzed using logistic regression. Results: Reductions in HAM-D17 total score at acute-phase endpoint were similar for desvenlafaxine- and escitalopram-treated women (−13.6 vs −14.3, respectively; P = 0.24). No significant difference was observed between groups at continuation-phase endpoint in the proportion of women who maintained response (desvenlafaxine, 82%; escitalopram, 80%; P = 0.70). In both phases, desvenlafaxine and escitalopram were generally safe and well tolerated. Conclusions: Among postmenopausal outpatients with MDD, there were no significant differences in the efficacy of desvenlafaxine and escitalopram based on primary efficacy analyses. The results do not support the overall hypothesis that the serotonin-norepinephrine reuptake inhibitor desvenlafaxine has an efficacy advantage for the treatment of MDD in postmenopausal women because, in this particular subgroup, desvenlafaxine failed to prove superiority over escitalopram. Safety and tolerability were comparable. Previous studies suggest that menopause status may exert an influence on the efficacy of certain classes of antidepressants. In this randomized, double-blind study for the treatment of postmenopausal women with depression, there were no significant differences between desvenlafaxine (serotonin-norepinephrine reuptake inhibitor) and escitalopram (selective serotonin reuptake inhibitor) with respect to efficacy, safety, or tolerability." @default.
• W2069496710 created "2016-06-24" @default.
• W2069496710 creator A5000830030 @default.
• W2069496710 creator A5015434278 @default.
• W2069496710 creator A5020995037 @default.
• W2069496710 creator A5028824765 @default.
• W2069496710 creator A5044626176 @default.
• W2069496710 creator A5048776340 @default.
• W2069496710 creator A5064943043 @default.
• W2069496710 creator A5068545843 @default.
• W2069496710 creator A5069796785 @default.
• W2069496710 creator A5085107940 @default.
• W2069496710 date "2010-07-01" @default.
• W2069496710 modified "2023-10-03" @default.
• W2069496710 title "Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder" @default.
• W2069496710 cites W1830258719 @default.
• W2069496710 cites W1899801274 @default.
• W2069496710 cites W1930767620 @default.
• W2069496710 cites W1969712323 @default.
• W2069496710 cites W1970133878 @default.
• W2069496710 cites W1996236818 @default.
• W2069496710 cites W2012766502 @default.
• W2069496710 cites W2013447731 @default.
• W2069496710 cites W2014781140 @default.
• W2069496710 cites W2022191212 @default.
• W2069496710 cites W2031214296 @default.
• W2069496710 cites W2043410495 @default.
• W2069496710 cites W2044018276 @default.
• W2069496710 cites W2054931962 @default.
• W2069496710 cites W2064293791 @default.
• W2069496710 cites W2078627160 @default.
• W2069496710 cites W2088140775 @default.
• W2069496710 cites W2092726363 @default.
• W2069496710 cites W2092727780 @default.
• W2069496710 cites W2096856326 @default.
• W2069496710 cites W2114613490 @default.
• W2069496710 cites W2115031069 @default.
• W2069496710 cites W2119459148 @default.
• W2069496710 cites W2129152730 @default.
• W2069496710 cites W2129953844 @default.
• W2069496710 cites W2131823335 @default.
• W2069496710 cites W2137296158 @default.
• W2069496710 cites W2155254553 @default.
• W2069496710 cites W2157547590 @default.
• W2069496710 cites W2158935477 @default.
• W2069496710 cites W2160070901 @default.
• W2069496710 cites W2170641360 @default.
• W2069496710 cites W2418300191 @default.
• W2069496710 cites W4231716456 @default.
• W2069496710 cites W4375907128 @default.
• W2069496710 doi "https://doi.org/10.1097/gme.0b013e3181d88962" @default.
• W2069496710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20539246" @default.
• W2069496710 hasPublicationYear "2010" @default.
• W2069496710 type Work @default.
• W2069496710 sameAs 2069496710 @default.
• W2069496710 citedByCount "45" @default.
• W2069496710 countsByYear W20694967102012 @default.
• W2069496710 countsByYear W20694967102013 @default.
• W2069496710 countsByYear W20694967102014 @default.
• W2069496710 countsByYear W20694967102015 @default.
• W2069496710 countsByYear W20694967102016 @default.
• W2069496710 countsByYear W20694967102017 @default.
• W2069496710 countsByYear W20694967102018 @default.
• W2069496710 countsByYear W20694967102019 @default.
• W2069496710 countsByYear W20694967102020 @default.
• W2069496710 countsByYear W20694967102021 @default.
• W2069496710 countsByYear W20694967102022 @default.
• W2069496710 countsByYear W20694967102023 @default.
• W2069496710 crossrefType "journal-article" @default.
• W2069496710 hasAuthorship W2069496710A5000830030 @default.
• W2069496710 hasAuthorship W2069496710A5015434278 @default.
• W2069496710 hasAuthorship W2069496710A5020995037 @default.
• W2069496710 hasAuthorship W2069496710A5028824765 @default.
• W2069496710 hasAuthorship W2069496710A5044626176 @default.
• W2069496710 hasAuthorship W2069496710A5048776340 @default.
• W2069496710 hasAuthorship W2069496710A5064943043 @default.
• W2069496710 hasAuthorship W2069496710A5068545843 @default.
• W2069496710 hasAuthorship W2069496710A5069796785 @default.
• W2069496710 hasAuthorship W2069496710A5085107940 @default.
• W2069496710 hasConcept C118552586 @default.
• W2069496710 hasConcept C126322002 @default.
• W2069496710 hasConcept C168563851 @default.
• W2069496710 hasConcept C197934379 @default.
• W2069496710 hasConcept C203092338 @default.
• W2069496710 hasConcept C2778375690 @default.
• W2069496710 hasConcept C2779144063 @default.
• W2069496710 hasConcept C2779177272 @default.
• W2069496710 hasConcept C2779583969 @default.
• W2069496710 hasConcept C2780051608 @default.
• W2069496710 hasConcept C2781161787 @default.
• W2069496710 hasConcept C71924100 @default.
• W2069496710 hasConceptScore W2069496710C118552586 @default.
• W2069496710 hasConceptScore W2069496710C126322002 @default.
• W2069496710 hasConceptScore W2069496710C168563851 @default.
• W2069496710 hasConceptScore W2069496710C197934379 @default.
• W2069496710 hasConceptScore W2069496710C203092338 @default.
• W2069496710 hasConceptScore W2069496710C2778375690 @default.
• W2069496710 hasConceptScore W2069496710C2779144063 @default.

• next